Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SREBF2 | Q12772 | 17/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 0.97 |
| ▸ | ATM | Q13315 | 3/20 | 0.97 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.97 |
| ▸ | SREBF1 | P36956 | 2/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.77 |
| ▸ | LMNA | P02545 | 2/20 | 0.77 |
| ▸ | RECQL | P46063 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fatostatin SCHEMBL2742732 | 1.00 | SREBF2 (1.00) | SREBF2MAPTATML3MBTL1ALDH1A1 | |
| Fatostatin SCHEMBL25327929 | 0.99 | MAPT (1.00) | SREBF2MAPTATML3MBTL1ALDH1A1 | |
| SCHEMBL19758233 | 0.95 | SREBF2 (0.90) | SREBF2MAPTATML3MBTL1ALDH1A1 | |
| SCHEMBL4279559 | 0.89 | SREBF2 (1.00) | SREBF2MAPTATML3MBTL1ALDH1A1 | |
| SCHEMBL4293604 | 0.88 | SREBF2 (1.00) | SREBF2MAPTATML3MBTL1ALDH1A1 | |
| SCHEMBL4290927 | 0.88 | SREBF2 (1.00) | SREBF2MAPTATML3MBTL1ALDH1A1 | |
| SCHEMBL4285116 | 0.88 | SREBF2 (1.00) | SREBF2MAPTATML3MBTL1ALDH1A1 | |
| SCHEMBL4286504 | 0.88 | SREBF2 (1.00) | SREBF2MAPTATML3MBTL1ALDH1A1 | |
| SCHEMBL4292296 | 0.88 | SREBF2 (1.00) | SREBF2MAPTATML3MBTL1ALDH1A1 | |
| SCHEMBL4283881 | 0.88 | SREBF2 (1.00) | SREBF2MAPTATML3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122031716-A | Carbon microsphere delivery carrier with controllable size in large range and preparation method and application thereof | 广州墨羲科技有限公司 | 2026-05-15 | — | — | CN | claimed |
| US-20250297321-A1 | METHOD FOR DETECTING METABOLIC REPROGRAMING OF CANCER TOWARDS FATTY ACIDS METABOLISM | INST NAT SANTE RECH MED (FR) | 2025-09-25 | — | — | US | claimed |
| CN-120114568-A | Application of Ras related protein Rab-3B in treatment of neuroblastoma | 大连市妇女儿童医疗中心(集团) | 2025-06-10 | — | — | CN | claimed |
| US-20250177367-A1 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | OHIO STATE INNOVATION FOUNDATION | 2025-06-05 | — | — | US | claimed |
| CN-119677539-A | Combination therapy for modulating lipid production | 俄亥俄州创新基金会 | 2025-03-21 | — | — | CN | claimed |
| US-20250049773-A1 | INHIBITION OF STEROL RESPONSE ELEMENT BINDING PROTEINS AS ATARGET FOR SELECTIVE ELIMINATION OF SENESCENT CELLS | TRUSTEES OF TUFTS COLLEGE | 2025-02-13 | — | — | US | claimed |
| CN-119386185-A | G6PD inhibitor and Fatostatin combined application for treating glioma | 潍坊市人民医院(潍坊市公共卫生临床中心) | 2025-02-07 | — | — | CN | claimed |
| EP-4489865-A2 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | Ohio State Innovation Foundation (US) | 2025-01-15 | — | — | EP | claimed |
| EP-4469602-A1 | METHOD FOR DETECTING METABOLIC REPROGRAMING OF CANCER TOWARDS FATTY ACIDS METABOLISM | Université Paris Cité (FR) | 2024-12-04 | — | — | EP | claimed |
| WO-2023172669-A9 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | OHIO STATE INNOVATION FOUNDATION (US) | 2024-08-02 | — | — | WO | claimed |
| US-12036218-B2 | Modulators of airway basal cells for the treatment or prevention of lung diseases | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e. V. (DE) | 2024-07-16 | — | — | US | claimed |
| CN-117414428-A | Combined use of G6PD inhibitors and inhibitors of novel molecular sites | 潍坊市人民医院(潍坊市公共卫生临床中心) | 2024-01-19 | — | — | CN | claimed |
| WO-2023172669-A2 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | OHIO STATE INNOVATION FOUNDATION (US) | 2023-09-14 | — | — | WO | claimed |
| WO-2023144357-A1 | METHOD FOR DETECTING METABOLIC REPROGRAMING OF CANCER TOWARDS FATTY ACIDS METABOLISM | UNIVERSITE PARIS CITE (FR) | 2023-08-03 | — | — | WO | claimed |
| EP-4219764-A1 | METHOD FOR DETECTING METABOLIC REPROGRAMING OF CANCER TOWARDS FATTY ACIDS METABOLISM | Université Paris Cité (FR) | 2023-08-02 | — | — | EP | claimed |
| WO-2023097280-A1 | INHIBITION OF STEROL RESPONSE ELEMENT BINDING PROTEINS AS A TARGET FOR SELECTIVE ELIMINATION OF SENESCENT CELLS | TRUSTEES OF TUFTS COLLEGE (US) | 2023-06-01 | — | — | WO | claimed |
| CN-116077493-A | Application of Fatostatin as medicine for treating atopic dermatitis, ointment and preparation method thereof | 中国人民解放军空军军医大学 | 2023-05-09 | — | — | CN | claimed |
| CN-115299453-B | Application of Fatostatin as synergist of insect growth regulator in preparing insecticide | 华南农业大学 | 2023-04-18 | — | — | CN | claimed |
| CN-115299453-A | Application of Fatostatin as synergist of insect growth regulator in preparing insecticide | 华南农业大学 | 2022-11-08 | — | — | CN | claimed |
| WO-2022120197-A1 | COMBINATIONS OF EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS AND STEROL REGULATORY ELEMENT-BINDING PROTEIN INHIBITORS FOR USES IN CANCER THERAPIES | EMORY UNIVERSITY (US) | 2022-06-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250049773-A1 | INHIBITION OF STEROL RESPONSE ELEMENT BINDING PROTEINS AS ATARGET FOR SELECTIVE ELIMINATION OF SENESCENT CELLS | SREBF1, SREBF2, OSBP | SREBF2 2/4885MAPT 3724/4885ATM 345/4885 |
| US-20250177367-A1 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | ACACB, SREBF2, FASN | SREBF2 2/4885MAPT 1292/4885ATM 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.